

Test Report: EN 13727 Chemical disinfectants and antiseptics – Quantitative suspension test for the evaluation of bactericidal activity in the medical area – Test method and requirements (phase 2, step 1)

Test Laboratory

BluTest Laboratories Ltd

Robertson Incubator (Level 4)
Robertson Building
56 Dumbarton Road
Glasgow
UK - G11 6NU

Identification of sample

Name of the product	Clinell Universal Wipes
Batch number	Not Provided
Client	GAMA Healthcare Ltd
Project Code	BT- GAM-13FT(2)(1)
Date of Delivery	18 August 2015
Storage conditions	Ambient
Active substances	Not Provided

Test Method and its validation

Method	Chemical neutralization
Neutralizer	Lecithin 11.7g/l, Polysorbate 80 100g/l, sodium thiosulphate 5.0g/l, sodium dodecyl sulphate 10.0g/l, sodium chloride 8.5g/l, tryptone 1.0g/l sterilized by autoclave.

Experimental Conditions

Period of analysis	18 August 2015 to 10 September 2015
Product test concentrations	100% v/v
Appearance product dilutions	Clear
Contact time	1 min; 2 min; 5 min ± 10s
Test temperature	20°C ± 1°C
Interfering substance	3.0 g/l bovine albumin + 3.0ml sheep erythrocytes
Stability of mixture	Stable
Temperature of incubation	37°C ± 1°C
Identification of strains	<i>Vancomycin resistant enterococci</i> (VRE) ATCC 12201 <i>Methicillin-resistant Staphylococcus aureus</i> (MRSA) UK16

EN 13727:2012. Results for the efficacy of Clinell Universal Wipes from GAMA Healthcare Ltd under DIRTY conditions

Test organisms	Validation test					Bacterial test suspension (N)	Contact time at 100.0% V/V		
	Bacterial Suspension (Nv)	Experimental conditions (A)	Bacterial suspension validation (NvB)	Neutralizer toxicity Control or filtration control (B)	Dilution-neutralization control or filtration test control (C)		1 min	2 mins	5 mins
VRE	Vc: 58 ; 70	Vc: 72 ; 74	Vc 61 ; 66	Vc 63 ; 67	Vc: 69 ; 75	10 ⁻⁷ : 253 ; 265	Vc 0 ; 0	1 ; 1	0 ; 0
							-1 0 ; 3	2 ; 2	0 ; 0
						10 ⁻⁸ : 26 ; 32	Na <1.40E+02	<1.40E+02	<1.40E+02
						N: 2.59E+09	R >10(6)	>10(6)	>10(6)
	Nv: 6.40E+02	A: 7.30E+01	Nv 6.35E+03	B: 6.50E+01	C: 7.20E+01				
Validation	30 ≤ Nv ₀ ≤ 160 ?	A ≥ 0.5 x Nv ₀ ?	30 ≤ Nv ₀ ≤ 160 ?	B ≥ 0.5 x NvB ?	C ≥ 0.5 x Nv ₀ ?	8.17 ≤ log N ₀ ≤ 8.70 ?	Test is valid		
	yes	yes	yes	yes	yes	yes			
MRSA UK16	Vc: 36 ; 48	Vc: 40 ; 41	Vc 34 ; 41	Vc 50 ; 64	Vc: 32 ; 44	10 ⁻⁷ : 142 ; 179	Vc 0 ; 0	0 ; 0	0 ; 0
							-1 0 ; 0	0 ; 0	0 ; 0
						10 ⁻⁸ : 10 ; 24	Na <1.40E+02	<1.40E+02	<1.40E+02
						N: 1.61E+09	R >10(6)	>10(6)	>10(6)
	Nv: 6.40E+02	A: 7.30E+01	Nv 6.35E+03	B: 6.50E+01	C: 7.20E+01				
Validation	30 ≤ Nv ₀ ≤ 160 ?	A ≥ 0.5 x Nv ₀ ?	30 ≤ Nv ₀ ≤ 160 ?	B ≥ 0.5 x NvB ?	C ≥ 0.5 x Nv ₀ ?	8.17 ≤ log N ₀ ≤ 8.70 ?	Test is valid		
	yes	yes	yes	yes	yes	yes			
Vc = viable count									
N = number of cfu/ml of the bacterial test suspension									
Nv = number of cfu/ml in the bacterial suspension									
R = reduction in viability									
Na = number of cfu/ml in the test mixture									
A = number of cfu/ml of the experimental conditions validation									
B = number of cfu/ml of the neutralizer toxicity validation or of the filtration validation									
C = the number of cfu/ml of the dilution-neutralization validation or the membrane filtration test validation									

Conclusion

According to EN 13727:2012, Clinell Universal Wipes **possesses** bactericidal activity at a minimum of > 6 log reduction at a concentration of **100% V/V** of the working concentration as tested after **1 minute** at 20°C under **DIRTY** conditions (3.0g/L bovine albumin + sheep erythrocytes) for *Vancomycin resistant enterococci* (VRE) ATCC 12201 and *Methicillin-resistant Staphylococcus aureus* (MRSA) UK16.

Signed



Dr Chris Woodall, Director
BluTest Laboratories Ltd
Glasgow, UK,
Date: 10 September 2015

DISCLAIMER

The results in this test report only pertain to the sample supplied.

BluTest (BT) has performed the testing detailed in this report using reasonable skill and care and has used reasonable endeavours to carry out the testing in accordance with an EN 13727 protocol. All forecasts, recommendations and results contained in this report are submitted in good faith. However, other than as expressly set out in this report, no warranty is given (i) in relation to the testing or the use(s) to which any results or deliverables produced in the course of the testing are or may be put by the Client or their fitness or suitability for any particular purpose or under any special conditions notwithstanding that any such purpose or conditions may have been made known to BT or (ii) that the intended results or deliverables from the testing can be achieved or (iii) that the Client can freely make use of the results or the deliverables without infringing any third party intellectual property rights and the Client will be deemed to have satisfied itself in this regard. BT shall have no liability (which is hereby excluded to the fullest extent permissible by law) in respect of any loss, liability or damage, including without limitation any indirect and/or consequential loss such as loss of profit or loss of business, market or goodwill, that the Client may suffer directly or indirectly as a result of or in connection with: (i) the performance of the testing; (ii) the use of any materials, samples or other information provided by the Client for use in the testing; and (iii) the Client's reliance upon or use of any results or deliverables provided as part of the testing.